X

Drug Profile

RAV 12

Alternative Names: ANTI-RAAG12-MAB; RAV12

Latest Information Update: 02 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Raven biotechnologies
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Cell membrane modulators; Complement activation stimulants; Immunostimulants; Signal transduction pathway modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Adenocarcinoma; Pancreatic cancer

Most Recent Events

01 May 2012 Discontinued - Phase-I/II for Adenocarcinoma in USA (IV)
01 May 2012 Discontinued - Phase-II for Pancreatic cancer in USA (IV)
17 Jul 2008 Raven biotechnologies has been acquired by MacroGenics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com